Latest News

In the Press /

Feb 16, 2022

Alvea Launches Scalable, Shelf- Stable DNA Vaccine Development against New SARS-CoV-2 Variants 2

Breakthrough DNA vaccine, Alveavax, enters pre-clinical testing for Omicron & BA.2 variants. Alvea, a startup biotechnology company, today announced that it will begin to develop, test, and deliver DNA vaccines at scale to low and middle income countries with limited access to existing vaccine options.

Feb 16, 2022

Announcing Alvea—A Covid-19 Vaccine Project

We’ve had effective COVID vaccines for more than a year, but there are still countries where less than 10% of people have received a dose. Omicron has been spreading for almost three months, but pharma companies have only just started testing variant-specific shots. mRNA vaccines are highly effective, but they’re hard to manufacture…

Alvea Updates /

Jul 31, 2022

Lessons from Developing a COVID Vaccine

Alvea’s CEO, Grigory Khimulya, reflects on lessons from the first six months of Alvea’s effort to bring a shelf-stable COVID-19 Omicron vaccine from idea to patients. He discusses inefficiencies in the clinical development process, what make’s Alvea’s culture and approach to clinical development different, and takes questions from the audience on a range of topics.